Clinical Trial

Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-02
notable Primary completion moved earlier: 2027-04-10 -> 2026-04-07 2026-07-02
Trial Details
NCT Number NCT07527078
Lead Sponsor Gan & Lee Pharmaceuticals.
Conditions Type 2 Diabetes (T2DM)
Enrollment 350 participants
Start Date 2026-04-07
Primary Completion 2026-04-07 (estimated)
Study Completion 2027-04-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-01